National Diabetes News
SGLT2 inhibitors linked to better kidney protection than GLP-1s in type 2 diabetes
Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor agonists for adults with type 2 diabetes, according to data published in JAMA Internal Medicine.
Do GLP-1 Supplements Work?
When it comes to managing diabetes and weight loss, GLP-1 medications have become a popular option. However, due to high out-of-pocket costs, drug shortages, and the fact that a prescription is needed to obtain these medications, people might be searching for other options. This is where dietary supplements have come into play.
A silent brain disease can quadruple dementia risk
Researchers studying nearly 2 million older adults found that cerebral amyloid angiopathy sharply raises the risk of developing dementia. Within five years, people with the condition were far more likely to be diagnosed than those without it. The increased risk was present even without a history of stroke. Experts say this makes early screening for memory and thinking changes especially important.
Tzield (Teplizumab) to Delay Type 1 Diabetes
Finding a cure for type 1 diabetes has been a priority in diabetes research for decades. Tzield (teplizumab), which was first approved by the FDA in 2022, has brought us one step closer by providing a way to delay the onset of type 1 diabetes. The medication marks an impressive milestone in diabetes research.
Time-restricted eating may reduce Crohn’s symptoms, inflammation by half
Crohn’s disease is a chronic condition that affects the intestines. It’s a common inflammatory bowel disease subtype. Long-term management can involve dietary changes to help manage symptoms. And experts have been interested in testing additional strategies to improve the symptoms and management of Crohn’s disease. A study published in Gastroenterology evaluated how time-restricted feeding (also called time-restricted eating), specifically eating only during an eight-hour window each day, affected individuals with Crohn’s disease.
Studies test whether gene-editing can fix high cholesterol. For now, take your medicine
Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix for high cholesterol. It’s very early stage research, tried in only a few dozen people so far. But gene-editing approaches being developed by two companies show hints that switching off certain genes could dramatically lower artery-clogging cholesterol, raising hopes of one day being able to prevent heart attacks without having to take pills.
